Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...

While Regeneron doesn't make vaccines specifically, its monoclonal antibody therapy provides a "passive vaccine" effect, ...

Currently, the flagship of Regeneron's oncology franchise is Libtayo (cemiplimab-rwlc), which is an anti-PD-1 monoclonal antibody that is approved for the treatment of several types of cancer.

The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable options, 2 are puts, totaling $104,155, and 14 are calls, amounting to $721 ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has ...

Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...

Mestag Therapeutics, a leading biotech company specialising in fibroblast immunology for inflammatory disease and cancer, has ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

While Regeneron doesn’t make vaccines specifically, its monoclonal antibody therapy provides a "passive vaccine" effect, temporarily protecting against infections. Dupixent Could Gain 30% More U ...